• 提示：詳情請下載說明書。

• 產(chǎn)品描述： MSX-122 (Q-122)是一種新型的CXCR4部分拮抗劑，IC50約為10 nM

• 靶點(diǎn)： CXCR4:~10 nM;CXCR

• 體外研究：
  MSX-122 is also incapable of blocking the binding of 125I-labeled CXCL12 to CXCR4. MSX-122 appears to be insufficiently large to block all binding sites between CXCR4 and CXCL12. MSX-122 blocks certain CXCR4 functions via binding to the CXCL12-binding site and interfering with CXCR4/CXCL12-mediated signaling. MSX-122 can intervene in the Gαi-signaling pathway (cAMP modulation), but not the Gq-pathway (calcium flux)

• 體內(nèi)研究：
  MSX-122 blocks bleomycin-induced lung fibrosis involving chemotaxis and homing of CXCR4-positive mesenchymal progenitor cells into the lungs. MSX-122 exhibits anti-inflammatory activity in a carrageenan-induced paw edema model. MSX-122 blocks lung metastasis of breast cancer and SCCHN, and liver metastasis of uveal melanoma in vivo

• 細(xì)胞實(shí)驗(yàn)： Cell lines: MDA-MB-231 cells Concentrations: 1, 10, 100, and 1000 nM Incubation Time: 15 mins Method: For binding affinity assay, MDA-MB-231 cells cultured in an 8-well slide chamber are preincubated with MSX-122 at 1, 10, 100, and 1000 nM. Then the cells are fixed with 4% formaldehyde and incubated with 50 nM biotinylated TN14003, and followed by Rhodamine staining.

• 動(dòng)物實(shí)驗(yàn)： Animal Models: Male C57BL/6 mice (age 5–6 weeks) Dosages: 10 mg/kg Administration: i.p. injection

• 參考文獻(xiàn)：
  1. Liang Z, et al. Development of a unique small molecule modulator of CXCR4. PLoS One. 2012, 7(4):e34038.

• 溶解性： Soluble  in  DMSO

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	3.421 ml	17.103 ml	34.207 ml
  5 mM	0.684 ml	3.421 ml	6.841 ml
  10 mM	0.342 ml	1.71 ml	3.421 ml
  50 mM	0.068 ml	0.342 ml	0.684 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號：

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *